London-based Boltz, which is developing AI models to speed up drug discovery, raised a $110M Series A led by Bessemer, after raising a $28M seed in 2025

London-based drug discovery startup Boltz raised $110 million in Series A funding led by Bessemer Venture Partners. The company, spun out of MIT, develops AI models to accelerate pharmaceutical research.
Why it matters
Major funding for AI drug discovery signals investor confidence in AI's ability to speed up expensive and time-consuming drug development processes.


